Entos Pharmaceuticals
Entos Pharmaceuticals is a clinical-stage company focused on developing genetic medicines using its proprietary Fusogenix™ PLV™ technology. This platform utilizes FAST fusion protein technology for direct fusion delivery of nucleic acids, aiming to create safe, effective, and redosable genetic therapies. The company leverages AI for precision targeting of organs, tissues, and cells beyond the liver. Entos has a pipeline of nucleic acid therapies addressing unmet clinical needs and collaborates with partners including Lilly, the Gates Foundation, and Oisín Bio. A significant development is their $198.5M partnership with the Canadian and Alberta governments to biomanufacture next-generation therapeutics.
Entos Pharmaceuticals
Entos Pharmaceuticals is a clinical-stage company focused on developing genetic medicines using its proprietary Fusogenix™ PLV™ technology. This platform utilizes FAST fusion protein technology for direct fusion delivery of nucleic acids, aiming to create safe, effective, and redosable genetic therapies. The company leverages AI for precision targeting of organs, tissues, and cells beyond the liver. Entos has a pipeline of nucleic acid therapies addressing unmet clinical needs and collaborates with partners including Lilly, the Gates Foundation, and Oisín Bio. A significant development is their $198.5M partnership with the Canadian and Alberta governments to biomanufacture next-generation therapeutics.